Weekly ReportOct 19–25, 2026
Sepsis, week 43 edition
We read 206 papers and selected 3.
Summary
This week’s sepsis literature highlighted a shift toward mechanistically defined host-response therapies, particularly regulation of inflammasomes, mitochondrial function, and immunometabolism. Preclinical studies identified taurine, the OCTN2–L-carnitine–pyrin axis, and POLRMT as potential targets for controlling hyperinflammation, while clinical studies emphasized rapid pathogen-directed therapy, biomarker-defined treatment heterogeneity, and diagnostic implementation. Additional evidence supported precision approaches to antimicrobial selection, dynamic physiologic phenotyping, post-sepsis survivorship care, and standardized sepsis definitions. The most important findings remain hypothesis-generating for novel therapies, but several implementation studies have immediate relevance to antimicrobial stewardship and risk stratification.
Selected Articles
1. Taurine lowers inflammaging by regulating the NLRP3 inflammasome in macrophages.
This study identified taurine as an immunometabolic regulator of NLRP3 inflammasome activation. Danger signals induced taurine efflux from macrophages, while taurine restoration suppressed trans-Golgi network disassembly, pyroptosis, and inflammatory signaling. Increasing taurine improved health span and reduced sepsis mortality in aged mice.
Impact: The paper provides a novel mechanistic link between taurine homeostasis, inflammasome biology, aging, and sepsis mortality, supported by human observations, cellular experiments, and aged-mouse models.
Clinical Implications: Taurine-based interventions may eventually become adjunctive therapies for inflammasome-dominant sepsis, but optimal dosing, timing, pathogen effects, safety, and human efficacy remain unknown. Clinical use is not currently justified.
Key Findings
- NLRP3 danger signals induced taurine efflux from macrophages as a proximal step in inflammasome activation.
- Taurine restoration suppressed trans-Golgi network disassembly, pyroptosis, and inflammatory signaling.
- Taurine elevation improved health span and reduced sepsis mortality in aged mice.
2. The pyrin inflammasome senses OCTN2-mediated uptake of extracellular ʟ-carnitine from muscle injury or ingestion.
This mechanistic study showed that extracellular L-carnitine activates the pyrin inflammasome after OCTN2-mediated uptake. L-carnitine repressed mevalonate synthesis, and both OCTN2 and pyrin were required for inflammatory responses to skeletal muscle injury. The findings establish a previously unrecognized link between muscle-derived metabolites, sterile inflammation, and innate immune activation.
Impact: The study identifies a highly novel molecular pathway linking muscle injury or dietary L-carnitine to inflammasome activation, offering a new framework for understanding tissue injury-associated inflammation in sepsis.
Clinical Implications: OCTN2, L-carnitine handling, mevalonate metabolism, or pyrin signaling could become therapeutic targets for sterile or sepsis-associated inflammation. Translation requires validation in human sepsis cohorts and clinically relevant infection models.
Key Findings
- Extracellular L-carnitine activated the pyrin inflammasome in LPS-challenged mice and murine and human macrophages.
- OCTN2-mediated uptake and repression of mevalonate synthesis were required for this inflammatory pathway.
- OCTN2 and pyrin were necessary for inflammatory responses to skeletal muscle injury.
3. Mitochondrial RNA polymerase is a critical mediator of LPS-induced inflammatory responses and septic shock.
This study identified POLRMT as a mitochondrial mediator of LPS-induced inflammatory signaling. Genetic depletion or pharmacological inhibition reduced cytokine production, mitochondrial activation, and NF-κB activity across human and murine macrophage systems. Myeloid POLRMT knockdown and oral IMT1 protected mice from LPS-induced septic shock.
Impact: The study provides convergent genetic and pharmacological evidence for a druggable mitochondrial node controlling inflammatory responses, with in vivo protection from septic shock.
Clinical Implications: POLRMT inhibition may support future host-directed therapy for hyperinflammatory septic shock, but mitochondrial toxicity, impaired immune defense, effects on bacterial clearance, and therapeutic window must be established before clinical translation.
Key Findings
- POLRMT deficiency reduced LPS-induced IL-1β, TNF-α, and IL-6 responses in human and murine macrophage-related systems.
- POLRMT regulated mitochondrial Complex I activity, ATP production, and NF-κB activation.
- Myeloid POLRMT knockdown and oral IMT1 reduced cytokines and protected mice from LPS-induced septic shock.